Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

491
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
491
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

443
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
443
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.3K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

140
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
140
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

763
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
763

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can we optimise the TB response amid funding constraints using evidence-based, cost-effective strategies.

IJTLD open·2026
Same author

Enhancing TB case detection: a case study of Kenya's Global Fund-supported public-private mix.

Public health action·2026
Same author

Building sustainable TB care systems: managing incentives in private sector engagement.

IJTLD open·2025
Same author

Caries status among 6-year-old children born with cleft lip and palate in Norway: a nationwide study.

Frontiers in oral health·2025
Same author

Leveraging Global Fund's investments to expand innovative public-private provider engagement in TB.

IJTLD open·2024
Same author

Measurement of the Fluctuations in the Number of Muons in Extensive Air Showers with the Pierre Auger Observatory.

Physical review letters·2021

Related Experiment Video

Updated: Dec 29, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K

Performance-based technical support for drug-resistant TB responses: lessons from the Green Light Committee.

M A Yassin1, K Samson2, E Wandwalo1

  • 1Global Fund to Fight AIDS, Tuberculosis and Malaria. Geneva.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|February 2, 2020
PubMed
Summary
This summary is machine-generated.

Drug-resistant tuberculosis (DR-TB) remains a global health challenge. The Green Light Committee (GLC) mechanism provides crucial technical assistance to scale up DR-TB response effectively.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.5K

Related Experiment Videos

Last Updated: Dec 29, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.5K

Area of Science:

  • Global health
  • Infectious diseases
  • Antimicrobial resistance

Background:

  • Drug-resistant tuberculosis (DR-TB) is a significant global health threat and a leading cause of death from antimicrobial resistance.
  • Despite advancements, substantial gaps persist in DR-TB treatment coverage, quality care access, and treatment outcomes.
  • Global Fund investments have been vital in expanding diagnostic tools, treatment, and patient-centered services for DR-TB.

Purpose of the Study:

  • To evaluate the role and evolution of the Green Light Committee (GLC) mechanism in addressing drug-resistant tuberculosis.
  • To highlight the importance of result-based technical assistance for scaling up DR-TB response.
  • To inform strategies for meeting United Nations General Assembly (UNGA) targets for DR-TB control.

Main Methods:

  • Review of the Green Light Committee (GLC) mechanism's evolution and impact over 10 years.
  • Analysis of lessons learned from demand-based technical assistance provided to countries for DR-TB response.
  • Assessment of the requirements for sustained technical support to meet global DR-TB targets.

Main Results:

  • The GLC mechanism has transitioned from project approval to providing tailored technical assistance.
  • A systematic, accountable, and results-based technical assistance model is critical for scaling up DR-TB response.
  • Sustained and predictable technical support is essential for countries to meet UNGA declaration targets.

Conclusions:

  • The GLC mechanism's model of technical assistance is effective in supporting DR-TB response scale-up.
  • Adapting and replicating this performance-based model can enhance global efforts against DR-TB.
  • Continued and consistent technical support is imperative to accelerate progress in combating drug-resistant tuberculosis.